Molbio Diagnostics experienced a sharp decline, dropping 8.8% to ₹1,229.65 on September 16, following profit booking after significant gains. Despite the recent downturn, the stock remains over 50% above its IPO price of ₹807, having surged 75% in the last month.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.